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Although the binding of endothelial cell protein C receptor (EPCR) to its ligands is well characterized at the biochemical level, it remains unclear how EPCR interaction with its ligands at the cell surface impacts its cellular trafficking. In the present study, we characterized the cellular localization and trafficking of EPCR in endothelial cells and a heterologus expression system. Immunofluorescence confocal microscopy studies revealed that a majority of EPCR is localized on the cell surface in membrane microdomains that are positive for caveolin-1. A small fraction of EPCR is also localized intracellularly in the recycling compartment. FVIIa or APC binding to EPCR promoted the internalization of EPCR. EPCR and EPCR-bound ligands were endocytosed rapidly via dynamin-and caveolar-dependent pathway. The endocytosed receptorligand complexes were accumulated in a recycling compartment before being targeted back to the cell surface. EPCR-mediated FVIIa endocytosis/recycling also resulted in transport of FVIIa from the apical to the basal side. In vivo studies in mice showed that blockade of EPCR with EPCR blocking antibodies impaired the early phase of FVIIa clearance. Overall our results show that FVIIa or APC binding to EPCR promotes EPCR endocytosis via the dynamin-dependent caveolar pathway, and EPCR-mediated endocytosis may facilitate the transcytosis of FVIIa and its clearance from the circulation.
For personal use only. on . by guest www.bloodjournal.org From Endothelial cell protein C receptor (EPCR) is a cellular receptor for protein C and activated protein C (APC). 1 It is primarily localized on the endothelial cells of large blood vessels and is very low or absent from the microvascular endothelium of most tissues. 2 Protein C binding to EPCR increases the rate of protein C activation by thrombin-thrombomodulin complexes. 3 EPCR, in addition to controlling the coagulation by modulating protein C-mediated anticoagulant pathway, has been shown to play an important role in many pathophysiological processes, such as inflammation responses to infection and trauma, hematopoiesis and autoimmunity. 4 Recent studies suggest that APC bound to EPCR activates protease-activated receptor-mediated cell signaling and this may be responsible for some of the non-hemostatic functions of EPCR. [5] [6] [7] [8] Our recent studies of FVIIa binding to endothelial cells revealed that EPCR also serves as a receptor for FVII and FVIIa on the endothelium. 9 In parallel studies, Preston et al. 10 also
found that FVIIa bound to soluble EPCR with a comparable affinity as of protein C. FVIIa binding to EPCR appeared to have no measurable consequences on FVIIa coagulant or cell signaling activities. 9 However, therapeutic concentrations of FVIIa, by competing with protein C and APC binding to EPCR, impaired EPCR-dependent protein C activation and APC-mediated cell signaling, respectively. More importantly, EPCR mediated the internalization of FVIIa bound to it on cell surfaces, indicating that EPCR may play a role in FVIIa clearance. 9 Although much is known about the biochemistry of EPCR and its interaction with protein C/APC, there is little information on how EPCR expression is regulated at the cell surface. It had been suggested that EPCR is homologous, and probably identical to intracellular murine protein, CCD41, a centrosomal protein. 11 Post-translational modification of EPCR/CCD41 gene product was shown to be responsible whether the protein is directed to the cell surface or the centrosome. 11 However, there were no other reports in the literature confirming this finding. At present, there is no information on intracellular distribution of human EPCR. Further, it is unclear how FVIIa or APC binding to EPCR modulates its cellular expression and the pathways by which EPCR mediates the internalization of FVIIa or APC.
In the present study, we characterized the cellular localization of EPCR in endothelial cells and CHO cells stably transfected with EPCR, mode of EPCR-mediated endocytosis and intracellular trafficking of the internalized ligands and the receptor.
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Radiolabeling
FVIIa and APC were labeled with 125 I using IODOGEN (Pierce, Rockford, IL)-coated polypropylene tubes and Na 125 I (Perkin-Elmer, Wellesley, MA) according to the manufacturer's technical bulletin and as described previously.
15,16

Fluorescent probe labeling
FVIIa and other EPCR ligands were labeled with AF488 using AF488 labeling kit and following the instructions provided in the manufacturer's technical bulletin (Molecular Probes, Invitrogen, USA). Approximately 100 µg of protein was used for each labeling. The degree of labeling, 3.7 to 4.0, was very similar among the labeled proteins.
Cell surface biotinylation and EPCR endocytosis
Biotinylation of cell surface proteins with NHS-S-S-biotin was performed as described earlier.
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The biotin-labeled cells were exposed to control vehicle, FVIIa or APC in buffer B (10 mM HEPES, 0.15 M NaCl, 4 mM KCl, 11 mM glucose, pH 7.4 (buffer A) containing 1 mg/ml BSA and 5 mM CaCl 2 ) for varying times at 37°C. Following the treatment, the cells were washed with PBS and the cell surface biotin was cleaved by incubating them with a cell-impermeable reducing buffer (50 mM glutathione, 1 mM MgCl 2 , 1.0 mM EDTA, 0.2% BSA and 75 mM NaCl, pH 8.0) for 10 min at 37 0 C. The cells were then washed with PBS and lysed in 200 µl lysis buffer (20 mM Tris-HCl, pH 7.4, containing 1 mM EDTA, 150 mM NaCl, 1% Triton X-100 and a cocktail of protease inhibitors) and the cell lysates were processed for EPCR immunoprecipitation.
Immunoprecipitation and western blotting
Cell lysates were incubated overnight at 4 0 C with EPCR mAb (JRK1496, 10 µg), followed by protein A/G agarose beads (20 µL) for 4 h. Following the removal of the cell lysate by centrifugation, the beads were washed 3 times with 10 mM Hepes buffer to remove the unbound material, and the bound material was eluted with 50 μL SDS-PAGE sample buffer.
Eluted samples (15 μL) were subjected to SDS-PAGE, followed by immuno blot analysis with streptavidin-HRP conjugate.
Disruption of caveolae-and coated-pit pathway-mediated internalization
For disruption of caveolae, the cells were treated with mβCD (10 mM) for 30 min. To inhibit the clathrin-coated pit pathway of internalization, the cells were rinsed in K + free buffer (20 mM For controls, cells were treated identically except that all buffer solutions contained 10 mM KCl.
Radioactivity-based internalization, degradation and recycling assays
Internalization and degradation of 125 I-labeled FVIIa and other ligands were determined as described recently. 9 To determine recycling of the internalized ligands, 125 I-labeled ligands (10 nM) in buffer B were incubated with CHO-EPCR cells for 2 h at 37°C to allow EPCR-mediated internalization. After 2 h incubation, the unbound ligand was removed, the cells were washed with buffer B and the cell surface-associated ligand was eluted by treating the cells with 0.1M glycine (pH 2.3) for 3 min. Thereafter, the cells were washed twice with buffer B and allowed to stand in buffer B at 37°C. At varying time intervals, the overlying buffer was removed and counted for the radioactivity.
Immunofluorescence-based internalization and recycling assays
Cells cultured on glass coverslips were incubated with FVIIa or other EPCR ligands (50 nM) that was tagged with fluorescent dye AF488 on ice-bath for 1 h to allow the binding of the ligand to EPCR with no or minimal internalization of the bound ligand. At the end of 1 h incubation, the unbound ligand was removed, the cells were washed once with cold buffer B, and then were warmed to 37°C to induce the internalization. At varying time intervals, the cells were fixed, permeabilized and processed for immunofluorescence confocal microscopy. For steady-state internalization studies, HUVEC or CHO-EPCR cells were incubated at 37°C for varying time periods with AF488-FVIIa or other AF488-conjugated ligands (50 nM). To monitor the endocytic pathway of FVIIa or APC, CHO-EPCR cells grown on glass coverslips were exposed to both AF488-FVIIa (or AF488-APC) (50 nM) and AF555-transferrin (300 nM) simultaneously for 5, 15
and 30 min. At the end of each time point, the cells were washed with cold buffer B and processed for immunofluorescence confocal microscopy. To monitor the recycling of the internalized ligands, CHO-EPCR cells were first incubated with AF488-conjugated FVIIa or APC (50 nM) for 1 h at 37°C, then the bound ligand was removed by washing the cells with buffer A containing 5 mM EDTA, and the cells were washed with buffer B and allowed to stay in buffer B at 37°C. After varying times at 37°C, the cells were fixed and processed for immunofluorescence confocal microscopy.
Immunofluorescence microscopy
The cells cultured on glass coverslips, control or exposed to FVIIa or other ligands as indicated in Results, were washed first in buffer B and then fixed for 1 h at 4°C in PBS containing 4% paraformaldehyde. The fixative was removed and the extra formaldehyde was quenched with 0.05% glycine, pH 8.0 for 5 min. The fixed cells were either permeabilized with 0.1% Triton X-100 in PBS for 10 min or left non-permeabilized and blocked with 3% goat serum in PBS for 1 h at room temperature. Both non-permeabilized and permeabilized cells were treated with EPCR monoclonal antibody (JRK-1500) (10 µg/ml) and/or rabbit polyclonal antibody for different organelle markers (2 to 5 µg/ml) for overnight at 4 0 C. After removing the unbound primary antibodies and washing them twice with PBS, the cells were incubated with Oregon Greenconjugated (excitation/emission wavelength 490/510 nm) or Rhodamine Red-conjugated (excitation/emission wavelength, 590/620 nm) anti-rabbit or anti-mouse IgG (4 µg/ml) for 60 min at room temperature. The cells were washed and the coverslips were mounted on a glass slide using aqueous gel mounting media (Biomedia) containing anti-fading agent.
Image acquisition, scoring and colocalization
Most of the immunostained cells were viewed using a Nikon Eclipse TE2000-5 (Japan) microscope at 60X magnification (oil) at room temperature. Images were acquired using UltraVIEW LCI confocal system (Perkin Elmer) as described recently. 17, 18 Perkin-Elmer's ImagingSuite™ (version 5.2) Acquisition & Processing Software was used for the acquisition of images, determining the co-localization and quantifying the signal (counting pixel value). Some of the confocal images were obtained using LSM510 Meta confocal system equipped with Axio Observer Z1 microscope (Zeiss, Germany).
Transcytosis of FVIIa
CHO, CHO-EPCR or HUVEC were seeded on to gelatin-coated (0.1 mg/ml for 10 min) membrane of the upper chamber of transwells (25,000 cells/12 mm diameter dish, polycarbonate membrane, 3 µm pore size, Corning Incorporated, NY, USA) and cultured for 5 days to form tight confluent monolayers. 125 I-FVIIa (10 nM) and BSA labeled with Evans Blue (0.67 mg/ml) were added to the upper chamber in 0.5 ml of medium. At varying times, a small aliquot was removed from the lower chamber (contains 1.5 ml of medium) and counted for the radioactivity to quantify FVIIa levels or measured absorbance at 650 nm to measure BSA levels. Committee of the University of Texas Health Science Center at Tyler. AF488-labeled human FVII or protein C was administered into anesthetized male C57BL/6 mice through tail vein (10 µg/mouse in 100 μl of saline). After one hour, the mice were sacrificed by exsanguination.
Various organs were collected and fixed in Excel fixative. After overnight fixation, the tissues were processed and stained with rabbit anti-AF488 antibodies and developed using AEC substrate chromogen (Dako North America Inc., Carpinteria, CA) and counterstained with hematoxylin. 
FVIIa clearance in mice
Results
Cellular distribution of endothelial cell protein C receptor
The surface and intracellular distribution of EPCR in endothelial cells and CHO cells stably transfected with EPCR were characterized by immunofluorescence confocal microscopy. As expected EPCR mAb brightly stained the cell surface of both non-permeabilized and permeabilized endothelial cells (Fig. 1A) . EPCR was distributed at the cell surface in a patchy or punctuate manner ( Figure S1 ). Analysis of Z-stack images showed that EPCR was distributed evenly on the entire cell surface with no evidence for preferential sorting to either apical or basolateral surfaces (data not shown). The status of cell confluency had no detectable effect on EPCR expression and localization ( Figure S1 ). In permeabilized endothelial cells, EPCR staining was also observed intracellularly, mostly around perinuclear region and some in dispersed dots throughout the cytoplasm (Fig. 1A) . In CHO-EPCR cells, EPCR intracellular staining was noted predominantly in single discreet intense patch at the juxtanuclear region of the cell and few small, dispersed dot-like structures in the cytoplasm beneath the plasma membrane ( To investigate whether the patchy or punctuate distribution of EPCR on the cell surface reflects EPCR localization in specialized membrane microdomains, such as caveolae, HUVEC and CHO-EPCR were stained with antibodies against EPCR and caveloin-1, the core protein of caveolae. Both EPCR and caveolin-1 were stained intensely at the cell surface of both the cell types and the overlap of EPCR and caveolin-1 immunofluorescence showed a high degree of colocalization (correlation coefficient of 0.866±0.015, n=10 and 0.945±0.009, n=10 in CHO-EPCR and HUVEC cells, respectively). Removal of membrane cholesterol from the plasma membrane by mβCD treatment, which disrupts caveolae and lipid rafts, led to uniform and smooth distribution of EPCR on the cell surface and markedly reduced the colocalization of EPCR and caveolin-1 (Fig. 1C ).
Since EPCR was localized in a dense cytoplasmic globular spot at a perinuclear position, an expected site of the centrosome, we tested whether EPCR localization at this vicinity represents the post-translational modified, signal peptide-deleted EPCR localization in the centrosome as reported earlier. 19 Wild-type CHO cells were transfected transiently with plasmid constructs expressing a full-length EPCR or EPCR lacking 15 amino acids at Nterminus (signal peptide) (ΔspEPCR) tagged with GFP at the C-terminus. The GFP fusion product of full length EPCR (EPCR-GFP) was localized to the cell surface as well as to the juxtanuclear region in side the cell (Fig. 1D ). In contrast, the signal peptide deleted EPCR-GFP fusion construct was distributed throughout the cytoplasm but not at the cell surface nor at the centrosomal location (Fig. 1D) . In additional studies, CHO-EPCR cells were immunostained for EPCR as well as γ -tubulin, a centrosomal marker. Although both EPCR and γ -tubulin were localized at the perinuclear vicinity, close examination revealed that EPCR is not colocalized with γ -tubulin (Fig. 1E ). The pericentriolar localization of EPCR may reflect EPCR localization in a recycling endosomal compartment (REC) as EPCR is colocalized with rab11, a marker for REC ( Fig. 1F ). EPCR localization in the REC was further confirmed by its colocalization with internalized transferrin, which is widely known to enter the recycling compartment following its internalization ( 
EPCR mediates FVIIa and APC internalization and undergo ligand-induced endocytosis
To evaluate EPCR-mediated FVIIa and APC internalization in endothelial cells using immunofluorescence confocal microscopy, HUVEC were exposed to FVIIa or APC (50 nM) conjugated with fluorescent dye, AF488 for varying time periods at 37°C. At 15 min, most of the AF488-FVIIa associated with endothelial cells was at the cell surface. By 30 and 60 min, AF488-FVIIa added to HUVEC were internalized and accumulated near a perinuclear location
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From with EPCR (Fig. 3A) . A similar internalization pattern was also observed with AF488-APC ( Figure S3A) . In additional studies, we also analyzed the internalization of FVII and protein C in endothelial cells. The data showed that FVII and protein C were internalized in a similar fashion as that of FVIIa and APC ( Figure S3B and Figure S3C ), suggesting that EPCR-mediated endocytosis of its ligands was independent of the protease activity of the ligands. Along with the ligands, the amount of EPCR in the REC was also increased significantly during this time period (Fig. 3C ). EPCR and the internalized ligands were colocalized extensively in the REC at 30 min. Thereafter, the amount of both the ligand and the receptor accumulated in the REC was decreased, suggesting sorting of the ligand and the receptor from the REC to the cell surface or lysosomal degradation pathway. FVIIa and APC internalization was very specific to EPCR-mediated process as we found no detectable internalization/accumulation of AF488-FVIIa or AF488-APC if the cell surface EPCR was blocked with EPCR blocking mAb (JRK1494)
prior to adding AF488-FVIIa or AF488-APC (data not shown). We also analyzed the internalization of active site-inhibited FVIIa and active site-inhibited APC. Consistent with the notion that EPCR-mediated endocytosis and recycling of FVIIa or APC is independent of its protease activity, we found no differences between the proteolytically active ligands and the inactive ligands in their binding to EPCR or their subsequent internalization and accumulation in the REC ( Figure S5A and Figure S5B ). and AF555-transferrin were localized in a dense patch at the pericentriolar area, which is the REC. AF488-APC followed a similar endocytic pathway as of AF488-FVIIa.
FVIIa and APC internalize via dynamin-and caveolae-dependent pathway
To determine the mechanism by which FVIIa and APC internalize, we tested different inhibitors for their ability to block the internalization. First, we determined whether FVIIa and APC internalize via a dynamin-dependent process by inhibiting dynamin-specific GTPase activity with the specific inhibitor, Dynasore. Dynasore treatment markedly attenuated the internalization of FVIIa and APC in CHO-EPCR cells ( Fig. 5A and 5D ). As expected, inhibition of dynamindependent pathway of internalization completely abolished the internalization of AF555-transferrin.
Next, we analyzed whether FVIIa and APC internalize via a clathrin-or caveolin-1-dependent pathway. Potassium depletion is known to inhibit the formation of clathrin-coated pits 20 and thus widely used to inhibit clathrin-dependent endocytosis. Potassium depletion completely blocked the internalization of transferrin. In contrast, potassium depletion failed to
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block the internalization of FVIIa or APC (Fig. 5B and 5D ). In fact, we observed an increase in FVIIa and APC internalization in potassium-depleted cells. This could be due to the presence of Mg ++ in the potassium-depletion buffer used in the assay as Mg ++ was found to increase the association of FVIIa and APC to EPCR 21 (unpublished data of the authors). To inhibit the caveolar-dependent pathway of internalization, CHO-EPCR cells were first treated with mβCD (10 mM) for 30 min to deplete membrane cholesterol, which disrupts caveolae, before adding the ligands. As shown in Fig. 4C , cholesterol depletion had no effect on the internalization of transferrin, which was known to be internalized via clathrin-coated pit pathway. In contrast to the lack of effect on transferrin internalization, mßCD treatment markedly inhibited the internalization of FVIIa and APC ( Fig. 5C and 5D ). Overall, our data suggest that FVIIa and APC internalize via the dynamin-and caveolar-dependent pathway.
Endocytosed FVIIa and APC recycle back to the cell surface
To determine the fate of internalized FVIIa or APC, first AF488-FVIIa or AF488-APC (50 nM) was allowed to internalize in CHO-EPCR cells, and then after removing the cell associated AF488-FVIIa or AF488-APC, the cells were allowed to stand at 37°C for varying time periods before they were processed for immunofluorescence microscopy. Fig. 6B and 6C ). The majority of the FVIIa or APC released into overlying media was intact (compare Fig. 6B and 6C) . SDS-PAGE analysis of the overlying media confirmed this. FVIIa secreted in to overlying media is functionally active (data not shown; APC activity was not tested). We found no significant increase in the cell associated 125 I- C or APC (100 nM) for 2 h at 37°C. As shown in Fig. 6D , exposure of the cells with EPCR ligands failed to reduce EPCR levels at the cell surface, indicating that endocytosed EPCR recycled back fully to the cell surface.
Rab11 regulate FVIIa recycling
Rab11 is localized to REC and plays an important role in the internalization and recycling through the REC. 22, 23 To examine the involvement of rab11 in FVIIa and APC internalization and recycling, CHO-EPCR cells were transiently transfected with wild-type, constitutively active (rab11 Q70L) or dominant negative (rab11 S25N) rab11 and the transfected cells were exposed to AF488-FVIIa or AF488-APC (50 nM). In cells expressing the wild-type and constitutively active form of rab11, the internalized AF488-FVIIa accumulated in the REC (Fig. 7) . In cells transfected with dominant negative rab11S25N, AF488-FVIIa did not accumulate in the REC but distributed through out the cytoplasm. These data indicate that rab11 regulates processing of the internalized FVIIa in to the REC. Similar findings were noted for APC (data not shown).
EPCR-mediated endocytosis/recycling: Potential physiological significance
To investigate the potential physiological role for EPCR-mediated endocytosis and recycling, we first examined whether EPCR-mediated endocytosis facilitates FVIIa transport across the cell, from the apical to the basal side. As shown in To investigate whether the above described mechanism operates in vivo, AF488-FVIIa or AF488-APC (10 µg/mice) were administered to mice via tail injection, and analyzed their distribution in the blood vessel using immunohistochemistry. As shown in Fig. 8B , both FVIIa and APC administered to mice were localized not only on endothelial cells lining blood vessels but also in the adventitia and extravascular tissue, suggesting FVIIa and APC bound to endothelium could enter extravascular space.
We also investigated whether blocking of FVIIa binding to EPCR in vivo impairs FVIIa clearance from the circulation. Before administering human FVIIa to mice, first we tested whether human FVIIa binds to mouse EPCR and this binding could be blocked by mEPCR blocking mAb. As shown in Figure S7 In contrast, blocking EPCR with the blocking antibodies significantly reduced FVIIa clearance from the circulation, particularly in the α -phase (t 1/2 of α -phase 30.7 ± 2.13 min; ß-phase 256 ± 52; n =3) .
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DISCUSSION
To gain the insights into the mechanism involved in EPCR endocytosis and the intracellular itinerary of the internalized ligands, we first characterized the cellular localization of EPCR. In this study we used endothelial cells, the cells that express EPCR in vivo, and a heterologous expression system (CHO cells stably transfected with EPCR), which allows to obtain more robust data and mechanistic information. EPCR in HUVEC and CHO-EPCR cells was predominantly localized on the cell surface with a small pool of EPCR in intracellular compartments. At the cell surface, EPCR appeared to be localized primarily in discrete plasma membrane microdomains. A high degree of EPCR colocalization with caveolin-1 in distinctive membrane microdomains suggest that EPCR is localized in caveolae. The present data is consistent with earlier observations that showed EPCR was fractionated into the low buoyant density membrane fractions where caveolin-1 and other proteins associated with lipid rafts and caveolae were found. 24, 25 EPCR localization in caveolae along PAR1 is thought to play an important role in APC-mediated cell signaling. 26 The caveolar localization of EPCR may also facilitate regulated release of EPCR from cells. 27 Most of the intracellular EPCR in both HUVEC and CHO-EPCR cells was concentrated juxtanuclearly at a dense cytoplasmic spot, an expected site of the centrosome or recycling compartment. Interestingly, earlier studies showed that cDNA encoding murine centrosomal protein CCD41 was identical with the cDNA for murine EPCR. 11 Further, using GFP technology, it was shown that the transfection of Ehrlich ascites tumor (EAT) cells with GFP fusion construct containing full-length CCD41 cDNA resulted in expression of the fusion protein at the cell surface whereas the GFP-fusion product lacking the signal peptide sequence was exclusively incorporated into a small perinuclear structure, which is the site of the centrosome. 11 Based on these data it was hypothesized that one single mRNA encodes the centrosomal protein CCD41
and the EPCR, and the post-translational modification, namely the deletion of signal peptide, is decisive for the centrosomal location of the protein while the unprocessed protein is incorporated into the cell membrane. The presence of EPCR in the early endosomes and the recycling compartment in untreated cells suggest that EPCR may be constitutively recycling. Although we were unable to obtain convincing evidence for the constitutive recycling of EPCR, one can not exclude the possibility of very fast internalization of EPCR constitutively coupled with rapid recycling back to the cell surface, which can not be captured by the present methodology. An earlier preliminary report suggested that EPCR was constitutively translocated into the nucleus. 28 In the present study, we failed to detect any translocation of EPCR into the nucleus, either constitutively or upon its occupancy by APC or FVIIa. The reason for the discrepancy between our present data and the earlier finding was unclear. Differences in cell model systems and/or experimental methodologies could have contributed to the difference. It is also conceivable that EPCR localized in the juxtanuclear position at the top or bottom of the nucleus might have given an appearance that EPCR was in the nucleus.
It had been speculated that EPCR may internalize APC and translocate it into the nucleus, which in turn could directly modulate the gene expression. 28, 29 It had been reported in preliminary studies that APC and not protein C was translocated into the nucleus. 28 The data presented here in clearly show that both APC and FVIIa bound to EPCR were internalized rapidly and in a time-dependent fashion. However, we found no evidence that the internalized ligands were transported into the nucleus. The internalized FVIIa and APC, along the endocytosed EPCR, were sorted into the recycling compartment. This was evident as the internalized FVIIa and APC followed the same route as of the internalized transferrin, which was known to enter the sorting endosomes following the internalization and then to the recycling endosomes. 22, 30 A high degree of colocalization of the internalized FVIIa or APC with transferrin, a reliable marker for the recycling endosome, further supports the above conclusion. We observed no detectable differences in the internalization and trafficking of FVIIa and APC or the zymogen forms of these enzymes, i.e., FVII and protein C. Consistent with this finding, inactivation of FVIIa's and APC's protease activity had no effect on their internalization and trafficking. It is unknown at present whether an injury to the endothelium could alter or influence the EPCR-mediated internalization and trafficking of its ligands. It is interesting to note that 29 showed that APC added to brain endothelial cells appeared to be transported intracellularly and into the nucleus under hypoxic conditions whereas it stayed on the cell surface in normoxic condition. These data need to be confirmed.
Endocytosis of EPCR was found to be mediated predominantly via the dynamin-and caveolin-1-dependent mechanism. Once internalized, most of the EPCR and its ligands were targeted from the sorting endosomes to the recycling compartment as we could see a clear, time-dependent accumulation of EPCR and its ligands in morphologically distinct pericentriolar compartment. From this compartment, both EPCR and the ligands were rapidly transported back to the cell surface. This was evident from marked decrease in FVIIa and EPCR levels in the recycling compartment between 30 to 60 min following the initiation of the endocytic process. This could explain why there was no decrease in EPCR levels at the cell surface even after prolonged incubation with FVIIa or APC. FVIIa or APC that was recycled back to the cell surface was intact and most of it was secreted into overlying medium rather than associating with the EPCR on the cell surface. This is expected since the affinity of FVIIa or APC to EPCR was in nano molar range (40 to 100 nM). Although we were unable to detect any internalized Fig.1D, E, F 
